CCS1477-02: a phase 1/2a study of CCS1477 in blood cancers, including relapsed or refractory non-Hodgkin lymphoma
A phase 1/2 trial evaluating CCS1477 in patients with non-Hodgkin Lymphoma (NHL)
This is a phase 1 (early phase) trial of an experimental treatment. Little is known about the safety and effectiveness of this treatment. You might not benefit from the treatment, but the trial will give important information about this new treatment, which could help other people in the future.
Trial aim and background
The aim of this trial is to find out more about a new treatment called CCS1477 for people with non-Hodgkin lymphoma and other types of blood cancer that have come back (relapsed) or has not responded (refractory) after previous treatment.
The trial aims to find out:
- the best dose of CCS1477 to use
- what side effects CCS1477 might have
- how well CCS1477 works
- how CCS1477 behaves in the body.
CCS1477 is a new targeted drug. It works by blocking particular types of proteins called histone acetyltransferases (HATs). HATs help control the way blood cells develop by altering the activity of genes and affecting what proteins a cell makes. Blocking the action of HATs can interfere with the development of cancerous blood cells.
Everyone in this trial has treatment with CCS1477. You have it as a capsule that you take by mouth (orally). You keep taking it until the trial finishes unless your lymphoma gets worse or you have troublesome side effects.
Who can enter
Adults with relapsed or refractory NHL which has been treated with one other treatment regimen may be eligible for this trial.
Locations
Recruitment is taking place in the following UK locations:
- University Hospital of Wales, Cardiff
- Western General Hospital, Edinburgh
- Gartnavel General Hospital, Glasgow
- Leicester Royal Infirmary, Leicester
- NIHR University College London Clinical Research Facility, London
- The Christie Hospital, Manchester
- Cancer and Haematology Centre, Oxford
- University Hospital of Southampton, Southampton
- The Royal Marsden, Sutton, Surrey
Further information
More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: clinicaltrials.gov/ct2/show/NCT04068597.
Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.